PMID- 33485303
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Jan 23
TI  - Light chain deposition disease involving kidney and liver in a patient with IgD 
      myeloma.
PG  - 40
LID - 10.1186/s12882-021-02246-9 [doi]
LID - 40
AB  - BACKGROUND: IgD multiple myeloma (MM) is a rare subtype of MM and light chain 
      deposition disease (LCDD) outside the kidney is also a rare and has scarcely been 
      reported. We report herein the details of the first reported case of LCDD 
      involving the kidney and liver co-occurring with IgD myeloma. CASE PRESENTATION: 
      A 66-year-old female with IgD MM presented with rapidly progressive acute renal 
      failure, ascites and pleural effusion. Immunofluorescent study of revealed the 
      characteristic linear deposition of Igkappa light chain along the glomerular and 
      tubular basement membrane in kidney. Electron microscopy showed the powdery 
      electron-dense deposits along the tubular and glomerular basement membrane 
      consistent with the diagnosis of LCDD. Laser microdissection followed by mass 
      spectrometry identified only Igkappa light chain with more than 95% probability 
      confirm the diagnosis of kappa-LCDD but not heavy/light chain deposition disease. 
      Liver biopsy with immunofluorescence study revealed the linear deposition of Igkappa 
      chain along the perisinusoidal space indicating the hepatic involvement of 
      kappa-LCDD. The patient was successfully treated with combination therapy with 
      bortezomib, cyclophosphamide, dexamethasone, and daratumumab. CONCLUSIONS: This 
      report emphasizes that prompt biopsy of affected organs and initiation of clone 
      directed therapy led to the correct diagnosis and favorable outcome in patient 
      with LCDD who has extrarenal involvement.
FAU - Tsushima, Takafumi
AU  - Tsushima T
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8601, Japan.
FAU - Suzuki, Tomo
AU  - Suzuki T
AD  - Division of Nephrology, Department of Medicine, Kameda Medical Center, 
      Kamogawa-shi, Chiba, 296-8601, Japan.
FAU - Terao, Toshiki
AU  - Terao T
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8601, Japan.
FAU - Miura, Daisuke
AU  - Miura D
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8601, Japan.
FAU - Narita, Kentaro
AU  - Narita K
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8601, Japan.
FAU - Takeuchi, Masami
AU  - Takeuchi M
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8601, Japan.
FAU - Shimuzu, Akira
AU  - Shimuzu A
AD  - Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
FAU - Matsue, Kosei
AU  - Matsue K
AD  - Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical 
      Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8601, Japan. 
      koseimatsue@gmail.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210123
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
RN  - 0 (Immunoglobulin D)
SB  - IM
MH  - Aged
MH  - Female
MH  - Humans
MH  - *Immunoglobulin D
MH  - Kidney Diseases/*immunology
MH  - Liver Diseases/*immunology
MH  - Multiple Myeloma/*complications/immunology
PMC - PMC7824927
OTO - NOTNLM
OT  - CyBorD
OT  - Daratumumab
OT  - IgD myeloma
OT  - Light chain deposition disease
OT  - Liver involvement
COIS- The authors declare that all authors have no competing interests.
EDAT- 2021/01/25 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/01/23
CRDT- 2021/01/24 20:25
PHST- 2020/10/12 00:00 [received]
PHST- 2021/01/01 00:00 [accepted]
PHST- 2021/01/24 20:25 [entrez]
PHST- 2021/01/25 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/01/23 00:00 [pmc-release]
AID - 10.1186/s12882-021-02246-9 [pii]
AID - 2246 [pii]
AID - 10.1186/s12882-021-02246-9 [doi]
PST - epublish
SO  - BMC Nephrol. 2021 Jan 23;22(1):40. doi: 10.1186/s12882-021-02246-9.